New York, May 26, 2026, 05:02 EDT
- Acrivon ended at $1.75 on May 22, off 2.23%. U.S. markets were closed for Memorial Day on Monday.
- CEO Peter Blume-Jensen will speak at TD Cowen’s Oncology Innovation Summit at 9:00 a.m. ET.
- Investors are watching for an interim readout on ACR-368 in serous endometrial cancer, scheduled for the second half of 2026.
Acrivon Therapeutics shares edged lower in premarket trade Tuesday as the cancer drug maker prepared for a TD Cowen oncology event after the long holiday break.
Shares on the Nasdaq finished Friday at $1.75, slipping 2.23%. The stock moved between $1.73 and $1.90 on 825,477 shares traded. StockAnalysis reported Acrivon at $1.74 in premarket trade at 4:38 a.m. EDT, off 0.57%.
The timing comes down to this: Acrivon president and CEO Peter Blume-Jensen is set for a virtual fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit at 9:00 a.m. ET, which is a half hour ahead of Nasdaq’s standard open.
Investors are watching for new data on ACR-368, or prexasertib, Acrivon’s top drug candidate, with the company saying it plans a prespecified interim look and a data update in the second half of 2026. The readout is expected from both “all-comer,” or biopsy-independent, serous endometrial cancer arms in the Phase 2b trial. SEC
U.S. stock markets were closed Monday for Memorial Day. Trading will resume Tuesday. Acrivon last traded at Friday’s closing level. Early in the session, biotech names were soft, with the SPDR S&P Biotech ETF at $131.66, down 0.8%.
Acrivon, which is still in the clinical stage, isn’t selling any drugs yet and remains far from the commercial footprint of bigger pharma. Its core product is AP3, a platform designed to detect protein pathway activity within cancer cells. The company says AP3 can help pair patients with appropriate drugs.
Blume-Jensen called 2026 “an important catalyst year” for Acrivon and said the company is “well positioned” for several clinical milestones. Acrivon posted a first-quarter net loss of $19.0 million, compared with a $19.7 million loss a year ago. The company reported $97.7 million in cash, cash equivalents and investments, plus $7.3 million from a later equity raise, and expects this to cover operations into the third quarter of 2027. SEC
Zentalis Pharmaceuticals is pushing ahead with azenosertib, its WEE1 inhibitor, now in ovarian cancer trials. The company said this month it gave the first dose in a Phase 3 confirmatory trial. Repare Therapeutics has a pipeline focused on cell-cycle and DNA-damage repair, including lunresertib, a PKMYT1 inhibitor, and camonsertib, an ATR inhibitor.
Acrivon put up a 52% confirmed overall response rate in serous endometrial cancer patients in an interim readout. That’s compared to 22% for the non-serous group.
But there’s risk on both sides. Acrivon is still a clinical-stage biotech losing money, and it says in its own filing that trial schedules, study outcomes and spending plans may turn out different than expected. If ACR-368 data disappoint, trial recruitment stalls, or management has to tap investors for cash earlier than hoped, the shares could come under pressure again.
For now the stock is moving on milestones, not revenue. The Cowen event on Tuesday might not have fresh trial data. But for a small biotech waiting on a second-half readout, investors are watching tone and timing.
